Kawaguchi-Suzuki M, Frye RF. The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection. Pharmacotherapy. 2013 Sep 30. doi: 10.1002/phar.1349. [Epub ahead of print] PubMed PMID: 24114761.
Wikoff WR, Frye RF, Zhu H, Gong Y, Boyle S, Churchill E, Cooper-Dehoff RM, Beitelshees AL, Chapman AB, Fiehn O, Johnson JA, Kaddurah-Daouk R; Pharmacometabolomics Research Network.
Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One. 2013;8(3):e57639. doi: 10.1371/journal.pone.0057639. Epub 2013 Mar 11. PubMed PMID: 23536766; PubMed Central PMCID: PMC3594230.
Joy MS, La M, Wang J, Bridges AS, Hu Y, Hogan SL, Frye RF, Blaisdell J, Goldstein JA, Dooley MA, Brouwer KL, Falk RJ.
Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. Br J Clin Pharmacol. 2012 Sep;74(3):445-55. doi: 10.1111/j.1365-2125.2012.04223.x. PubMed PMID: 22380717; PubMed Central PMCID: PMC3477346.
Ardjomand-Woelkart K, Kollroser M, Magnes C, Sinner F, Frye RF, Derendorf H, Bauer R, Butterweck V.
Absolute/relative bioavailability and metabolism of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides (tetraenes) after intravenous and oral single doses to rats. Planta Med. 2011 Nov;77(16):1794-9. doi: 10.1055/s-0030-1271120. Epub 2011 May 20. PubMed PMID: 21604240.